2022 Circulars

MCAZ Circular 20 of 2022 CBD products clarification

Invitation to stakeholders meetings

Circular 19 of 2022 – Fees Schedule

Circular 16 of 2022 Publication of Cancelled Wholesale Dealers’ Permit, Premises and Persons’ Licences.

Circular-15-of-2022-Safety-measures-for-sodium-valproate-and-the-risk-of-congenital-malformations-in-neonates-and-neurodevelopmental-disorders-in-children-exposed-to-sodium-valproate-during-pregnancy

Circular 13 of 2022 Pharmacovigilance system requirements for Pharmaceutical Industry

Circular 11 of 2022 Revised MCAZ Clinical Trial Guidelines

Circular 9 of 2022 Inspection of Premises prior to renewal of Licences and Permits

Circular 8 of 2022 -Publication of Cancelled Wholesale Dealers’ Permit and Persons’ Licences

circular 06 of 2022- Renewal of Wholesale Dealers

Circular 02 of 2022- Renewal of Pharmacies

Circular 3 of 2022 – Clarification of Conditions for Medicines Registration Requirements and Subsequent Expansion of Registration Certificate, Section 15 Format Annexure

Annex1-Template-for-comments-on-Draft-Guideline-for-market-Authorization-Renewal

DRAFT GUIDELINES FOR MARKET AUTHORISATION RENEWALS

Circular 5 of 2022 – Publication of Cancelled Premises and Persons’ Licences.